{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'The infusion rate may be reduced and the dose may be interrupted or held based on tolerability.', 'The first and second infusions will be administered over approximately 90 minutes (but not less', 'than 80 minutes). Subsequent infusions will be administered over approximately 60 minutes (but', 'not less than 50 minutes), providing there are no significant infusion-associated events.', '9.4.2 Identity of Investigational Products', '9.4.2.1 Teprotumumab', 'Teprotumumab (HZN-001) is a fully human anti-IGF-1R mAb. The physiochemical properties', 'were previously presented in Section 7.1.3.1. Teprotumumab will be provided in single-dose', '20 mL glass vials as a freeze-dried powder containing, in addition to the drug substance,', '20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose, and 0.01% polysorbate 20 (w/w).', 'Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be', 'reconstituted with 10 mL of water for injection. The resulting solution has an approximate', 'concentration of 50 mg/ mL teprotumumab. The reconstituted teprotumumab solution must be', 'further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration (see', 'Section 9.4.6.3 for details).', '9.4.2.2 Placebo', 'Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL', 'or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.', '9.4.3 Labeling', 'Study drug packaging will be in compliance with Sponsor/CRO standard procedures and will', 'meet all local requirements.', 'Upon arrival of investigational products at the site, the investigational pharmacist or site', 'personnel not assigned to the study should check them for damage and verify proper identity,', 'quantity, integrity of seals, and temperature conditions, and report any deviations or product', 'complaints to the monitor/Sponsor upon discovery.', '9.4.4 Storage', 'Recommended storage conditions for the freeze-dried teprotumumab drug product are between', '2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F), protected from light. Storage at ambient temperature of the', 'reconstituted teprotumumab solution should be limited to 4 hours. For batch-specific information', 'on shelf-life, see the packaging.', 'The IV infusion should be administered at room temperature (20\u00b0C to 24\u00b0C [68\u00b0F to 75\u00b0F]). The', 'diluted product should be used within 4 hours of preparation. However, if not used within', '4 hours, and if dilution has taken place under controlled and validated aseptic conditions, the', 'infusion solution can be stored for up to 24 hours at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). An', 'Investigational Pharmacy Manual will be provided to all sites and further describe these', 'processes in detail.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 71 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'At the clinic, all study medications must be stored in a secure area with limited access, and a', 'daily temperature log of the drug storage area will be maintained every working day; deviations', 'from the specified temperature range will be reported as protocol deviations.', '9.4.5 Drug Accountability', 'The Principal Investigator at each site is responsible for the control of all study medication and', 'delegating infusion bag preparation and drug accountability responsibilities to an unmasked', 'pharmacist (or designee in accordance with institutional policies and local regulations), who', 'must maintain adequate records of the receipt and disposition of all study medication shipped to', 'the study center. Records will include receipt dates, condition at time of receipt, quantities', 'received, quantities dispensed, quantities returned or destroyed, and the identification numbers of', 'the subjects who received study medication.', 'As permitted by site policy, all empty, partially empty, and full vials of study drug must be', 'retained by the study center under locked storage until drug accountability has been completed.', 'Periodically throughout the study and at the conclusion of the study, inventory checks and', 'accountability of study materials will be conducted by an unmasked representative of the', \"Sponsor. Once accountability is completed, the Sponsor's representative will authorize the return\", 'of study medication (all used, partially used, and unused vials) to the 3rd party vendor (see', 'Table 6.1). The completed Drug Accountability and Drug Return/Destruction Record(s) will be', \"returned to the unmasked CRO manager. The Investigator's copy of the Drug Accountability and\", 'Drug Return/Destruction Record(s) must document accurately the return of all study drug', 'supplies and be maintained by the unmasked pharmacist or designee until the study is complete', 'and the database is locked. Records will also include disposition dates and quantities returned to', 'the designated facility.', '9.4.6 Study Drug Administration and Timing of Dose for each Subject', '9.4.6.1 Description of Clinical Supplies', 'will supply study drug to clinical sites. Ancillary supplies for dosing', 'will be provided by the study site (i.e., infusion bags containing normal saline, infusion', 'administration sets, syringes, needles, alcohol swabs, gauze pads, bandages, and biohazard', 'containers for safe storage of used needles and syringes).', '9.4.6.2 Determination of Dose Volume', 'The volume of study drug to be administered will be determined by the interactive web response', \"system (IWRS) and will be based on the subject's weight. The first dose will be 10 mg/kg, and\", 'subsequent doses will be 20 mg/kg. Weight will be measured at Screening and Weeks 12 and 24', 'during the Treatment Period. The dose on Day 1 of the double-masked Treatment Period will be', 'based on the Screening weight. The weight obtained at Week 12 can be used to adjust the dose', 'beginning at Week 12 or Week 15, as appropriate.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 72 of 117']\n\n###\n\n", "completion": "END"}